Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver).
Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently ruling this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.
Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently ruling this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.
Location: United Kingdom, England, London
Employees: 1-10
Total raised: $8.83M
Founded date: 2021
Investors 4
| Date | Name | Website |
| 01.12.2023 | Ada Ventur... | adaventure... |
| 12.11.2022 | Fifty Year... | fiftyyears... |
| - | Verve Vent... | verve.vc |
| - | Formic Ven... | formic.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.05.2023 | - | $6.28M | Ada Ventur... |
| 31.01.2022 | Seed | $2.55M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.07.2024 | Leading innovation: 10 promising European startups focusing on biopharmaceuticals | Biopharmaceuticals, often known as bio-pharma, represent a dynamic sector within the pharmaceutical industry that uses biological processes to develop drugs and therapies. Unlike traditional pharmaceuticals, which are typically synthesized ... |
| 09.05.2023 | MultiOmic Health Secures $6.2 Million | MMC Ventures was proud to participate in the round, alongside Hoxton Ventures, Ada Ventures, and Verve Ventures. Existing treatments for metabolic syndrome-related conditions merely reduce risk or delay onset of serious consequences such a... |
| 05.05.2023 | UK’s MultiOmic Health secures €5.7M for its AI-enabled precision drug discovery platform | London-based Multiomic Health, a company building an AI-enabled precision therapeutics discovery platform for metabolic syndrome diseases, announced on Thursday, May 4, that it has secured £5M (approximately €5.71M) in a Seed extension roun... |
| 04.05.2023 | MultiOmic Health Closes $6.2M Funding Round | MultiOmic Health, a London, UK-based artificial intelligence (AI)-enabled drug discovery company, raised $6.2M in funding. The round was led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures. The comp... |
| - | Multiomic Health | “AI-Enabled Precision Medicine for Metabolic Syndrome” |